报价延迟最少15分钟:2025/07/21 18:51 EDT
盘后时段
|
||||
|
1.5 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.49
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.77/-0.42
|
|
企业价值
188.47M
|
| 资产负债 |
|
每股账面净值
-0.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.07
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 18:51 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal sprayto be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). |
